TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01130181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01923766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotoxic T lymphocytes (CTLs).
Description: This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated.
Study: NCT04851574

Intervention type: DRUG
Intervention: Sugammadex Injection
Description: Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.

Intervention type: DRUG
Intervention: Sugammadex Injection
Description: Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.

Intervention type: DRUG
Intervention: Sugammadex Injection
Description: Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
Study: NCT04014426

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary sample
Description: Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)

Intervention type: OTHER
Group type: OTHER
Intervention: Urinary sample
Description: Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)
Study: NCT02604459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral oximeter (Fore-Sight)
Description: The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: depth of anesthesia monitor (BIS)
Description: The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BP management
Description: The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
Study: NCT01550744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Form = Injection, route = subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Form = Injection, route = subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Form = Injection, route = subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Form = Injection, route = subcutaneous
Study: NCT02604459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be used in both groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia will be used in both groups
Study: NCT01550744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form = Injection, route = subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form = Injection, route = subcutaneous
Study: NCT03716245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supraclavicular lymph node dissection
Description: people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular area radiotherapy
Description: people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
Study: NCT03678324

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI and fast bound-pool fraction imaging
Description: Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey.
Study: NCT02523196

Intervention type: DRUG
Group type: OTHER
Intervention: HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)
Description: The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease

Intervention type: DEVICE
Group type: OTHER
Intervention: Hepatic Venous Pressure Gradient (HVPG)
Description: Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
Study: NCT02468492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma injection into knee versus placebo (saline) injection.
Study: NCT02604459

Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anesthesia
Description: General anesthesia will be used in both groups
Study: NCT02468492

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Platelet rich plasma injection into knee versus placebo (saline) injection.
Study: NCT03570086

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic
Description: using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
Study: NCT02604459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be used in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol per protocol
Study: NCT02604459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Description: propofol per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: fentanyl per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl
Description: fentanyl per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane
Study: NCT00677079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Body weight adjusted dose~1 hour intravenous infusion
Study: NCT00222352

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care cTnL testing
Description: The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half.
Study: NCT02604459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: maintenance of anesthesia with inhaled sevoflurane
Study: NCT04478903

Intervention type: OTHER
Intervention: Questionnaire
Description: Zarit Burden Inventory French version and SF12
Study: NCT06290518

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ligilactobacillus salivarius CECT5713
Description: Oral administration of a capsule containing 9.5 log10 cfu of the strain.
Study: NCT04537741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography
Description: all patients being included will undergo CCTA before invasive coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography
Description: all patients being included will undergo CCTA before invasive coronary angiography
Study: NCT01138475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 1 microgram by mouth daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 5000 IU (international units) by mouth daily for 6 weeks
Study: NCT06290518

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of a capsule containing maltodextrin.
Study: NCT01138475

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance, one capsule daily for 6 weeks
Study: NCT02423486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation therapy (BIOCON-2000)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation therapy with biofeedback
Study: NCT02373618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DN and conventional PT
Description: Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
Study: NCT03325465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
Study: NCT03161548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14
Study: NCT04344730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mechanical ventilation
Description: The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
Study: NCT03618381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ EGFR806-EGFRt
Description: Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Description: Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Study: NCT03907397

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Protein
Description: up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)

Intervention type: OTHER
Group type: OTHER
Intervention: Continued peanut avoidance
Description: Standard of care avoidance of peanut
Study: NCT02448134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Access
Description: Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
Study: NCT01387750

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mentholated Cream
Description: A topical cream containing menthol without the addition of the oxygenated glycerol triesters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mentholated Cream with OGT
Description: A Topical Cream that contained both menthol and oxygenated glycerol triesters.
Study: NCT01560221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Workplace
Description: Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
Study: NCT02132403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTH1704
Description: BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPRIME PGG
Description: Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
Study: NCT01560221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
Study: NCT02132403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
Study: NCT03767543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study: NCT01791517

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 1 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 1 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 1 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 2 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 2 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 2 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
Study: NCT01560221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
Study: NCT02636920

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Education to the Patient (TEP)
Description: * Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients.
Study: NCT01791517

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 3 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 3 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 3 (Test)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 4 (Control)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 4 (Control)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order

Intervention type: OTHER
Group type: OTHER
Intervention: Solution 4 (Control)
Description: Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
Study: NCT04595786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 20mg/kg TXA was prepared in a 50ml syringe for intravenous pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline was prepared in a 50ml syringe for intravenous pump
Study: NCT03767257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam Pill
Description: For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
Study: NCT03161548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue conservation surgery
Description: Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative CCRT
Description: Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy